S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  649--A
 
                        2021-2022 Regular Sessions
 
                             I N  S E N A T E
 
                                (PREFILED)
 
                              January 6, 2021
                                ___________
 
 Introduced  by Sen. HARCKHAM -- read twice and ordered printed, and when
   printed to be committed  to  the  Committee  on  Health  --  committee
   discharged, bill amended, ordered reprinted as amended and recommitted
   to said committee

 AN  ACT  to  amend the social services law and the public health law, in
   relation to medication for the treatment of substance use disorders
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Subdivision 2 of section 365-a of the social services law
 is amended by adding a new paragraph (gg) to read as follows:
   (GG) ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG  ACTING  INJECTABLE
 NALTREXONE  FOR  DETOXIFICATION  OR MAINTENANCE TREATMENT OF A SUBSTANCE
 USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES-
 SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.    SUCH
 MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI-
 ZATION MANDATE.
   §  2. Subdivision 26-b of section 364-j of the social services law, as
 added by section 4 of part B of chapter 69  of  the  laws  of  2016,  is
 amended to read as follows:
   26-b. Managed care providers shall not require prior authorization for
 [an  initial  or  renewal  prescription  for buprenorphine or injectable
 naltrexone  for  detoxification  or  maintenance  treatment  of   opioid
 addiction  unless  the prescription is for a non-preferred or non-formu-
 lary form of the drug or as otherwise required by section 1927(k)(6)  of
 the  Social  Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG
 ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT
 OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO  GENERALLY  ACCEPTED
 NATIONAL  PROFESSIONAL  GUIDELINES  FOR THE TREATMENT OF A SUBSTANCE USE
 DISORDER.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
              

                                                            LBD00371-03-1

 S. 649--A                           2
 
   § 3. Subdivision 10 of section  273  of  the  public  health  law,  as
 amended  by  section  7 of part GG of chapter 56 of the laws of 2020, is
 amended to read as follows:
   10.  Prior  authorization  shall  not  be  required for [an initial or
 renewal prescription for  buprenorphine  or  injectable  naltrexone  for
 detoxification  or  maintenance treatment of opioid addiction unless the
 prescription is for a non-preferred or non-formulary form of  such  drug
 as  otherwise required by section 1927(k)(6) of the Social Security Act.
 Further, prior authorization shall not be required  for]  ANY  BUPRENOR-
 PHINE PRODUCTS, methadone, [when used for opioid use disorder and admin-
 istered  or  dispensed  in  an  opioid treatment program] OR LONG ACTING
 INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT  OF  A
 SUBSTANCE  USE  DISORDER  PRESCRIBED  ACCORDING  TO  GENERALLY  ACCEPTED
 NATIONAL PROFESSIONAL GUIDELINES FOR THE TREATMENT OF  A  SUBSTANCE  USE
 DISORDER.
   §  4.  This  act shall take effect on the ninetieth day after it shall
 have become a law; provided, however, that the amendments to subdivision
 26-b of section 364-j of the social services law made by section two  of
 this  act  shall  not  affect  the  repeal of such section, and shall be
 deemed repealed therewith.